093 Tear fluid dupilumab levels of patients with moderate-to-severe atopic dermatitis and ocular surface disease

Ocular surface disease (OSD) is a common adverse event in dupilumab-treated patients with atopic dermatitis (AD). The pathomechanism remains unclear. At present, no data are available on dupilumab levels the eyes of these patients. aim this study to measure tear fluid after 4 and 28 weeks treatment. This prospective included moderate-to-severe AD Patients were seen by dermatologist an ophthalmologist at start dupilumab, Tear was collected using standard Schirmer’s test, stored -80 °C. strips eluted, fluids both combined. Serum samples also obtained Dupilumab measured serum liquid chromatography tandem mass spectrometry. A total 48 included. Based severity OSD week treatment, had slightly higher their compared or mild (median 0.25 mg/L (interquartile range (IQR) 0.19-0.61) vs. 0.22 (IQR 0.13-0.55), p=0.353). difference reached significance treatment 0.55 0.35-1.31) 0.29 0.16-0.60) OSD, p=0.021). No found between OSD. In conclusion, during Further research needed investigate implications increased dupilumab.